Bone marrow-derived CD13^+ cells sustain tumor progression

A potential non-malignant target for anticancer therapy

Eleonora Dondossola^1, Angelo Corti^2, Richard L Sidman^3,4, Wadih Arap^5,6,*, and Renata Pasqualini^5,6,*

^1David H. Koch Center; The University of Texas M.D. Anderson Cancer Center; Houston, TX USA; ^2Division of Molecular Oncology; San Raffaele Scientific Institute; Milan, Italy; ^3Harvard Medical School; Boston, MA USA; ^4Department of Neurology; Beth Israel-Deaconess Medical Center; Boston, MA USA; ^5University of New Mexico Cancer Center; Albuquerque, NM USA; ^6Division of Hematology/Oncology and Division of Molecular Medicine; Department of Internal Medicine; University of New Mexico School of Medicine; Albuquerque, NM USA

**Keywords:** angiogenesis, tumor, CD13, mouse models, bone marrow-derived cells

Angiogenesis, the formation of new blood vessels from pre-existing ones, is essential for the development of most solid tumors. While angiogenesis in normal tissues is tightly coordinated by the activity of various anti- and pro-angiogenic factors, the formation of new blood vessels within neoplastic lesions is sustained by the imbalanced expression of pro-angiogenic mediators. This generally involves a functional interplay between malignant cells and several of their non-malignant counterparts that populate the tumor microenvironment, including endothelial cells, pericytes, and fibroblasts. Tumor-infiltrating bone marrow-derived cells (BMDCs), such as tumor-associated macrophages (TAMs), Tie2-expressing monocytes (TEMs), mast cells, granulocytes, dendritic cells, and myeloid suppressor cells, may also promote angiogenesis in the tumor microenvironment by producing soluble mediators that stimulate the proliferation, migration, and functional differentiation of endothelial cells. In addition, angiogenesis critically relies on several extracellular proteases that activate growth factors, inhibit suppressive mediators, and/or promote extracellular matrix (ECM) degradation along with tissue remodeling.

We have previously shown that alanyl (membrane) aminopeptidase (ANPEP, best known as CD13) is one of the proteolytic enzymes involved in angiogenesis and tumor growth. CD13 is a membrane-bound metalloproteinase expressed in tumors by endothelial cells, pericytes and fibroblasts, as well as by some neoplastic cells. Different immunoreactive forms of CD13 are also expressed by many non-malignant cells of normal tissues, including some types of epithelial cells, keratinocytes, mast cells, myeloid cells, and antigen-presenting cells. In physiological conditions, CD13 operates quite broadly in protein degradation, antigen presentation, signal transduction, differentiation, proliferation, adhesion and migration, and also regulates various hormones and cytokines. In addition, CD13 has been involved in the epithelial-to-mesenchymal transition, hence promoting tumor progression. Our group has shown CD13 to have a functional role in angiogenesis both in normal and neoplastic tissues. In line with this notion, newborn CD13-null mice exhibit a reduced angiogenic response to hypoxia in a model of oxygen-induced retinopathy of prematurity. Furthermore, adult CD13-null mice display reduced angiogenesis and limited tumor growth rates than their wild-type (WT) counterparts. Although these results indicated that CD13 participates in pathological angiogenesis, the specific cell types involved were not identified in these studies.

To dissect the relative contributions of different CD13^+ cells to abnormal angiogenesis, we have recently investigated the growth of B16F10 melanomas, TSA mammary adenocarcinomas and Lewis lung carcinomas (LLC) subcutaneously implanted into 4 different syngeneic murine models: (1) WT mice transplanted with WT BMDCs recovered from isogenic donors (WT^+); (2) CD13-null (KO) mice transplanted with WT BMDCs (KO^WT); (3) WT mice transplanted with CD13-null BMDCs (KO^WT); and (4) CD13-null mice transplanted with CD13-null BMDCs recovered from isogenic donors (KO^KO) (Fig. 1). Tumor growth was
severely impaired in mice lacking CD13⁺ BMDCs (WT⁺⁺ and KO⁺⁺), correlating with a reduction in both vascular density and pericycle coverage within residual neoplastic lesions. Notably, the growth of TSA and LLC cells was restored in KO⁺⁺ mice, which fail to express CD13 on pericytes, endothelial cells and fibroblasts but are reconstituted with CD13⁺ BMDCs. Of note, the absence of CD13⁺ BMDCs in KOko and WTko mice markedly reduced the metastatic dissemination to the lung of cancer cells administered intravenously, suggesting that CD13⁺ BMDCs promote angiogenesis at both primary and secondary tumor sites. Moreover, the administration of CD45⁺CD11b⁺CD13⁺ myeloid cells isolated from TSA tumors grown in WT mice could by itself increase the number of blood vessels (as well as their pericycle coverage) that serving tumors implanted in KO mice. These CD45⁺CD11b⁺CD13⁺ cells, which consisted mainly of macrophages, specifically localized to the tumor microenvironment and produced soluble pro-angiogenic factors such as matrix metalloproteinase 9 (MMP9) and chemokine (C-C motif) ligand 2 (CCL2, also known as MCP1). Given that both MMP9 and CCL2 are known to recruit pericytes, hence consolidating vascular architecture, these findings indicate that CD13⁺ myeloid BMDCs are likely to sustain tumor progression by attracting pericytes and thus promoting angiogenesis and vascular maturation.

Our findings establish CD13⁺ BMDCs as a previously unrecognized non-malignant candidate for the development of new anticancer therapies. CD13 inhibitors and neutralizing antibodies have previously been shown to limit angiogenesis and hence inhibit tumor growth. The observation that CD13⁺ BMDCs are almost exclusively localized within neoplastic lesions makes them an attractive target for ligand-directed delivery of biological response modifiers and/or drugs. For example, CD13 ligands as well as molecules that bind other receptors selectively expressed by CD13⁺ BMDCs could be exploited for the targeted delivery of cytotoxic compounds. Interestingly, previous studies have shown that CD13 is expressed in different immunoreactive forms by tumor-associated blood vessels, myeloid cells, and epithelial cells, and that the vasculature-associated variant of CD13 is selectively recognized by peptides containing an NGR motif. This very small domain, which we identified by in vivo phage display technology, has been exploited to selectively deliver chemotherapeutic drugs, cytokines, pro-apoptotic peptides, liposomes, viruses, vascular-targeting, and/or imaging agents to tumor blood vessels, resulting in significant therapeutic responses or improvements in imaging procedures. Although CD13⁺ BMDCs are not recognized by NGR-containing ligands, perhaps as they express a form of CD13 that differs from that found on endothelial cells and/or owing to vascular accessibility issues, other ligands targeting the BMDC-associated variant of CD13 or other markers might be developed to target this cell subset, as previously accomplished with endothelial cells. In summary, the discovery that CD13⁺ BMDCs promote tumor growth and angiogenesis has potential therapeutic implications that merit further investigation. If our finding were confirmed in translational settings, this newly recognized cell subpopulation could serve as a non-malignant target for the development of novel anticancer therapies.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.
References


2. De Palma M, Naldini L. Role of hematopoietic cells and endothelial progenitors in tumor angiogenesis. Biochim Biophys Acta 2006; 1766:159-66; PMID:16857321


